However, our study showed that the patients with elevated baseline NSE levels faced a 1.7‐fold increased risk of worse OS compared to those with normal NSE levels, suggesting that NSE may hold prognostic value in lung cancer patients receiving anlotinib therapy. This evidence concerns the gene ENO2 and lung cancer.